

# Drug Coverage Decision for B.C. PharmaCare

# **About PharmaCare**

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

# **Details of Drug Reviewed**

Drug	trientine
Brand Name	Waymade-trientine
Dosage Form(s)	250 mg capsule
Manufacturer	Waymade Canada Inc.
Submission Type	New Submission
Use Reviewed	Wilson's disease
Common Drug Review (CDR)	Yes, the CDR recommended: <b>to Reimburse with clinical criteria and/or conditions</b> . Visit the CDR website for more details: <a href="www.cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf">www.cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf</a>
Provincial Review	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC advised that because Waymade-trientine is similar to some of the other drugs used for the treatment of Wilson's disease, the Ministry may accept the CDEC's recommendation for Waymade-trientine.
Drug Coverage Decision	Limited Coverage Benefit Access the trientine criteria. Access the trientine criteria from:  www.gov.bc.ca/pharmacarespecialauthority
Date	October 25, 2022
Reason(s)	<ul> <li>Drug coverage decision is consistent with CDR recommendation</li> <li>Trientine was similar to d-penicillamine in patients with Wilson's disease in respect to efficacy.</li> <li>Treatment discontinuations due to adverse events were more common with d-penicillamine compared with trientine.</li> <li>Based on the Limited Coverage criteria and cost, trientine will be available to patients with intolerance to d-penicillamine.</li> </ul>
Other Information	None

# The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the <u>Drug Benefit Council (DBC)</u> gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

### This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.